The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shots begin

Sun, 17th Jan 2021 18:28

(Adds details on doses, Sao Paulo governor comments)

By Jamie McGeever and Pedro Fonseca

BRASILIA/RIO DE JANEIRO, Jan 17 (Reuters) - Brazilian health
regulator Anvisa on Sunday approved emergency use of COVID-19
vaccines from China's Sinovac Biotech Ltd and Britain's
AstraZeneca, clearing the way for immunizations as the
pandemic enters a deadly second wave.

Minutes after Anvisa's board voted unanimously to approve
both vaccines, Monica Calazans, a 54-year-old nurse in Sao
Paulo, became the first person to be inoculated in the country,
receiving the Chinese vaccine known as CoronaVac.

President Jair Bolsonaro, a coronavirus skeptic who has
refused to take a vaccine himself, is under growing pressure to
start inoculations in Brazil, which has lost more than 200,000
to COVID-19 – the worst death toll outside the United States.
(Graphic: https://tmsnrt.rs/34pvUyi)

Delays with vaccine shipments and testing results have held
up vaccinations in the country, once a global leader in mass
immunizations and now a regional laggard after countries such as
Chile and Mexico started giving shots last month.

Bolsonaro's government aims to kick off a national
immunization program this week but is waiting on shipments of
the AstraZeneca vaccine at the center of its plans. That has
added to public frustration and offered a political rival the
chance to upstage the right-wing president.

Sao Paulo Governor Joao Doria, who oversees the Butantan
biomedical center that is partnered with Sinovac in Brazil, said
Anvisa's decision was a triumph for science as he gave the
go-ahead for the first vaccination in his state.

"A victory for science. A victory for life. A victory for
Brazil," Doria tweeted.

Bolsonaro, for whom Doria is a potential center-right rival
to his 2022 re-election efforts, has taunted the governor over
CoronaVac's disappointing 50% efficacy in Brazilian trials. But
the federal Health Ministry has agreed to acquire and distribute
the shot for the national immunization drive.

Health Minister Eduardo Pazuello told a news conference that
the rush to start vaccinating immediately was an illegal
"marketing ploy" and the government would start distributing the
vaccines to states on Monday, with the nationwide immunization
plan beginning on Wednesday.

Brazil could eventually vaccinate 1 million people a day, he
said.

Adding to the urgency for vaccinations, a second wave of the
outbreak in Brazil is snowballing as the country confronts a
new, potentially more contagious variant of the coronavirus that
originated in Amazonas state and prompted Britain and Italy to
bar entry to Brazilians.

Butantan, which is set up to fill and finish CoronaVac doses
on its production line, plans to supply 46 million doses of the
two-dose shot by April, the institute said in a statement. Some
6 million of those are ready to go.

The federally funded Fiocruz institute is still waiting for
a delayed shipment of the active ingredient in the AstraZeneca
vaccine for finishing on a Rio de Janeiro assembly line.

The Health Ministry has scrambled to line up 2 million ready
doses of the AstraZeneca vaccine from India, but officials there
have suggested it may take weeks to approve exports. Pazuello
said on Sunday he expected the doses from India this week.

(Reporting by Eduardo Simoes in Sao Paulo, Pedro Fonseca in Rio
de Janeiro, Jamie McGeever and Ricardo Brito in Brasilia;
Editing by Brad Haynes, Lisa Shumaker and Peter Cooney)

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.